Rachel Huai-En Chang

Rachel Huai-En Chang

Auto-generated profile, based on publicly available information

Rachel Huai-En Chang

Internal Medicine, Kaiser Permanente Mid-Atlantic States, Gaithersburg, MD, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2023 in Clinical Nutrition
Verified
Journal Article
Closed access
STShuyue Tuo
Shuyue Tuo
YYYee Hui Yeo
Yee Hui Yeo
RCRachel Chang
Rachel Chang
ZWZhang Wen
Zhang Wen
QRQiuju Ran
Qiuju Ran
XTXinxing Tantai
Xinxing Tantai

25 March 2021 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
HHHuei-Kai Huang
Huei-Kai Huang
KBKhulood Bukhari
Khulood Bukhari
CPCarol Chiung‐Hui Peng
Carol Chiung‐Hui Peng
DHDuan‐Pei Hung
Duan‐Pei Hung
MSMing-Chieh Shih
Ming-Chieh Shih
Yu-Kang TuYu-Kang Tu
Yu-Kang Tu

30 June 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
CPCarol Chiung-Hui Peng
Carol Chiung-Hui Peng
Yu-Kang TuYu-Kang Tu
Yu-Kang Tu
GLGin Yi Lee
Gin Yi Lee
RCRachel Huai-En Chang
Rachel Huai-En Chang
YHYuting Huang
Yuting Huang
KMKashif Munir
Kashif Munir
Context Whether proton pump inhibitors (PPI) can improve glycemic control among individuals with diabetes or decrease the risk of incident diabetes in the general population is unclear. Objective To evaluate the impact of PPI therapy on glycemic control among individuals with diabetes and the risk of diabetes among those without diabetes. Results PubMed, Embase, Scopus, and ClinicalTrials.gov were searched from inception to November 21, 2020. We included studies comparing glycosylated hemoglobin (HbA1c) or fasting blood glucose (FBG) among individuals with diabetes treated with and without PPI therapy as an add-on to standard therapy. Studies evaluating the risk of incident diabetes among individuals taking PPI were assessed. We performed dual independent review, data extraction, and quality assessment. Weighted mean differences between groups or relative risks were imputed using random-effects models. Results Seven studies (n = 342) for glycemic control and 5 studies (n = 244 439) for risk of incident diabetes were included. Compared with standard therapy, add-on PPI was associated with a significant decrease in HbA1c (WMD, −0.36 %; 95% CI, −0.68 to −0.05; P = 0.025) and FBG (WMD, −10.0 mg/dL; 95% CI, −19.4 to −0.6; P = 0.037). PPI use did not reduce the risk of incident diabetes (pooled RR, 1.10; 95% CI, 0.89 to 1.34; P = 0.385). Conclusion Add-on PPI improved glycemic indices among individuals with diabetes but did not alter the risk of incident diabetes. The effects of PPI on glycemic control should be considered when prescribing antacids to patients with diabetes.

6 April 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
HHHuei-Kai Huang
Huei-Kai Huang
CPCarol Chiung‐Hui Peng
Carol Chiung‐Hui Peng
SLShu‐Man Lin
Shu‐Man Lin
KMKashif Munir
Kashif Munir
RCRachel Huai‐En Chang
Rachel Huai‐En Chang
Yu-Kang TuYu-Kang Tu
Yu-Kang Tu
Background: Evidence on the differences in fracture risk associated with non‐vitamin K antagonist oral anticoagulants (NOAC) and warfarin is inconsistent and inconclusive. We conducted a systematic review and meta‐analysis to assess the fracture risk associated with NOACs and warfarin. Methods and Results: We searched PubMed, Embase, Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov from inception until May 19, 2020. We included studies presenting measurements (regardless of primary/secondary/tertiary/safety outcomes) for any fracture in both NOAC and warfarin users. Two or more reviewers independently screened relevant articles, extracted data, and performed quality assessments. Data were retrieved to synthesize the pooled relative risk (RR) of fractures associated with NOACs versus warfarin. Random‐effects models were used for data synthesis. We included 29 studies (5 cohort studies and 24 randomized controlled trials) with 388 209 patients. Patients treated with NOACs had lower risks of fracture than those treated with warfarin (pooled RR, 0.84; 95% CI, 0.77–0.91; P <0.001) with low heterogeneity ( I 2 =38.9%). NOACs were also associated with significantly lower risks of hip fracture than warfarin (pooled RR, 0.89; 95% CI, 0.81–0.98; P =0.023). A nonsignificant trend of lower vertebral fracture risk in NOAC users was also observed (pooled RR, 0.74; 95% CI, 0.54–1.01; P =0.061). Subgroup analyses for individual NOACs demonstrated that dabigatran, rivaroxaban, and apixaban were significantly associated with lower fracture risks. Furthermore, the data synthesis results from randomized controlled trials and real‐world cohort studies were quite consistent, indicating the robustness of our findings. Conclusions: Compared with warfarin, NOACs are associated with lower risks of bone fracture.

1 May 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
KBKhulood Bukhari
Khulood Bukhari
HHHuei-Kai Huang
Huei-Kai Huang
DHDuan-Pei Hung
Duan-Pei Hung
CPCarol Chiung-Hui Peng
Carol Chiung-Hui Peng
MSMing-Chieh Shih
Ming-Chieh Shih
KMKashif Munir
Kashif Munir
Introduction: Several studies have linked obesity to more severe illness and higher mortality in COVID-19 patients. However, the relationship between being underweight and COVID-19 mortality remains inconclusive. Previous dose-response meta-analyses did not enroll or specifically analyze the underweight population. Herein, we conducted a systematic review and dose-response meta-analysis to investigate the relationship between body mass index (BMI) and mortality in both obese and underweight patients with COVID-19. Methods: We searched PubMed, Embase, Cochrane Library, Scopus, and Web of Science databases from inception until August 12, 2020 using the keywords “COVID-19,” “body mass index,” “obesity,” “overweight”, and “underweight.” Three reviewers independently assessed the relevant articles, including the title, abstract, and full text, to identify eligible studies. We performed a two-stage random-effects dose-response meta-analysis, including only studies with at least three quantitative classifications for BMI. The nonlinear trend was evaluated using a restricted cubic splines model with three-knots at the 10th, 50th, and 90th percentiles. A sensitivity analysis was conducted by pooling only those studies which specifically evaluated underweight patients (BMI<18.5 kg/m2). Results: Thirteen studies comprising 25,828 patients were included in the analysis. In the linear model, the mortality of patients with COVID-19 increased by 1.5% for each 1-kg/m2 increase in BMI (pooled relative risk [RR] =1.015, 95% confidence interval [CI] =1.004−1.027). However, a significant non-linear relationship between BMI and mortality was observed (Wald test: Pnon-linearity<0.001). We demonstrated a J-shaped curve, indicating that both underweight and obese patients had a higher mortality than those with normal weight. Interestingly, overweight patients (BMI, 25−30 kg/m2) seemed to have the lowest mortality risk. Using a BMI of 15 kg/m2 as the reference, the RRs of mortality decreased with BMI, and this trend continued until BMI of approximately 28 kg/m2 (RR=0.743, 95% CI=0.576−0.959). The relationship between BMI and mortality was then reversed, and an upward trend was observed when BMI exceeded 30 kg/m2; the RRs (95% CI) at BMIs 30, 35, 40, and 45 kg/m2 were 0.745 (0.570−0.974), 0.841 (0.643−1.100), 1.082 (0.850−1.377), and 1.457 (1.129−1.879), respectively. Conclusion: This study is the first dose-response meta-analysis that showed both underweight and obese COVID-19 patients are at higher risk of increased mortality. A J-curve relationship was demonstrated between BMI and COVID-19 mortality.

17 December 2020
Verified
Report
Open access
HHHuei-Kai Huang
Huei-Kai Huang
KBKhulood Bukhari
Khulood Bukhari
DHDuan-Pei Hung
Duan-Pei Hung
RCRachel Huai-En Chang
Rachel Huai-En Chang
CPCarol Chiung-Hui Peng
Carol Chiung-Hui Peng
Yu-Kang TuYu-Kang Tu
Yu-Kang Tu
INPLASY2020120090 Association between body mass index and mortality in patients with COVID-19: a systematic review and meta-analysis Keywords: COVID-19; body mass index; obesity; overweight; underweight; mortality. Download PDF – 2020120090